ADC Congress Asia 2025: (Non SG- Asia Biopharma)

The Antibody Drug Conjugate (ADC) industry is poised for a transformative leap, with a surge of deals, innovations, and collaborations spotlighting Asia as the hub for next-generation ADC development. Asia is leading the way in advancing beyond traditional biosimilars, delving into novel payloads, conjugation technologies, and linkers. This heightened interest in ADCs is driven by the rising global incidence of cancer, which increases the demand for advanced therapeutic options. Breakthroughs in antibody technology are significantly boosting ADC efficacy and specificity, opening new possibilities for targeted treatments. This progress is bolstered by escalating investments and a growing number of FDA approvals, highlighting the field's potential and gaining regulatory confidence.

Despite these exciting developments, the ADC sector faces critical challenges that demand innovative solutions and strategic planning. High development costs, intricate manufacturing processes, and potential toxicities are notable hurdles that require thoughtful strategies to overcome.

ADC Asia Congress 2025 will provide a crucial platform that will bring together pioneers and key opinion leaders across mega-pharma and biotechnology focusing on Singapore, China, Japan, South Korea, Australia and the rest of Asia Pacific to discuss the latest technological innovations, clinical development, strategic collaborations, and common hurdles in the development of ADCs in the region.

Event Highlights:

• Hear from 40+ leading industry experts and visionaries in the ADC field from Singapore, China, Japan, South Korea, and Australia on the latest advancements and future directions of Antibody Drug Conjugates.

• Engage with 300+ attendees to explore forward-looking perspectives on ADC research and development and discover how strategic collaborations can drive innovation.

• Delve into Asia-Pacific-specific challenges and opportunities in ADC development.

• Discover real-world applications and success stories from top researchers and companies in the Asia-Pacific region.

• Explore breakthrough technologies and methodologies shaping the future of ADC development, including novel conjugation techniques and advanced drug delivery systems.

ADC 2025 is co-located with the 12th Annual Biologics Manufacturing Asia 2025, 9th Annual Biologistics World Asia 2025, 3rd Clinical Trial Festival Asia 2025, Biologics Digitilisation & A.I. World, and Asia-Pacific Bioprocessing Excellence Awards Gala Dinner 2025.

Host or Publisher IMAPAC Pte Ltd